TY - JOUR
T1 - Long-term Results of Ahmed Glaucoma Valve Implantation for Uveitic Glaucoma
AU - Papadaki, Thekla G.
AU - Zacharopoulos, Ioannis P.
AU - Pasquale, Louis R.
AU - Christen, William B.
AU - Netland, Peter A.
AU - Foster, C. Stephen
N1 - Funding Information:
This study was supported in part by a Postgraduate Scholarship from the Embeirikion Foundation, Crete, Greece (T.G.P., I.P.Z.). The authors indicate no financial conflict of interest. Involved in design of study (C.S.F., T.G.P.); data collection and literature search (T.G.P., I.P.Z.); analysis and interpretation of data and writing of the article (T.G.P., W.B.C.); critical revision and final approval of the article (L.R.P., P.A.N., C.S.F.). The study and data accumulation were carried out with approval from the Human Research Committee of the Massachusetts Eye and Ear Infirmary. Informed consent to review their files was obtained from the patients, and the study was in accordance with the Health Insurance Portability and Accountability Act regulations.
PY - 2007/7
Y1 - 2007/7
N2 - Purpose: To present long-term outcomes of Ahmed glaucoma valve implantation for uveitic glaucoma. Design: Interventional case series. Methods: Retrospective chart review of 60 patients (60 eyes) with uveitic glaucoma who underwent Ahmed valve implantation over a four-year period at a tertiary uveitis referral center. Success definition 1 included patients with an intraocular pressure (IOP) between 5 and 21 mm Hg, reduced by 25% from that before implantation. Success definition 2 (qualified success) excluded those patients in whom serious complications occurred. Results: Mean follow-up time was 30 months (range, six to 87 months; four-year results relate to a cohort of 15 patients). Success rates were 77% and 50% and qualified success rates were 57% and 39% at one and four years, respectively. At four years, 74% of the patients required glaucoma medication to maintain IOP control. The overall complication rate was 12%/person-years. The rate of visual acuity loss was 4%/person-years; that was most commonly attributed to corneal complications that were more likely to occur in patients with preoperative corneal disease (P = .01, Fisher exact test). Conclusions: Ahmed glaucoma valve implantation is a safe yet moderately successful procedure for uveitic glaucoma. Long-term success rates are enhanced with the use of glaucoma medications, and corneal complications are the most common of all potential serious complications.
AB - Purpose: To present long-term outcomes of Ahmed glaucoma valve implantation for uveitic glaucoma. Design: Interventional case series. Methods: Retrospective chart review of 60 patients (60 eyes) with uveitic glaucoma who underwent Ahmed valve implantation over a four-year period at a tertiary uveitis referral center. Success definition 1 included patients with an intraocular pressure (IOP) between 5 and 21 mm Hg, reduced by 25% from that before implantation. Success definition 2 (qualified success) excluded those patients in whom serious complications occurred. Results: Mean follow-up time was 30 months (range, six to 87 months; four-year results relate to a cohort of 15 patients). Success rates were 77% and 50% and qualified success rates were 57% and 39% at one and four years, respectively. At four years, 74% of the patients required glaucoma medication to maintain IOP control. The overall complication rate was 12%/person-years. The rate of visual acuity loss was 4%/person-years; that was most commonly attributed to corneal complications that were more likely to occur in patients with preoperative corneal disease (P = .01, Fisher exact test). Conclusions: Ahmed glaucoma valve implantation is a safe yet moderately successful procedure for uveitic glaucoma. Long-term success rates are enhanced with the use of glaucoma medications, and corneal complications are the most common of all potential serious complications.
UR - http://www.scopus.com/inward/record.url?scp=34250698567&partnerID=8YFLogxK
U2 - 10.1016/j.ajo.2007.03.013
DO - 10.1016/j.ajo.2007.03.013
M3 - Article
C2 - 17493574
AN - SCOPUS:34250698567
SN - 0002-9394
VL - 144
SP - 62-69.e2
JO - American Journal of Ophthalmology
JF - American Journal of Ophthalmology
IS - 1
ER -